Company Intelligence

PostEra

PostEra is building a modern 21st century biopharma. We're using our advances in machine learning to accelerate Medicinal Chemistry and bring more cures to patients. PostEra advances small molecule programs through partnerships with biopharma while also…

In this profile

Quick Facts

  • Founded 2020
  • Headquarters Boston, United States
  • Country United States
  • Industry AI in Healthcare
  • Company Type Growth
  • Status Active
  • Website Official site
  • Last Reviewed Aug 2026

Executive Summary

PostEra is building a modern 21st century biopharma. We're using our advances in machine learning to accelerate Medicinal Chemistry and bring more cures to patients. PostEra advances small molecule programs through partnerships with biopharma while also advancing its own internal pipeline. We've raised $26M from top investors and closed $1Bn in AI partnerships, signing multi-year agreements with Amgen, Pfizer and the NIH. PostEra also launched and led the world's largest open-science drug discovery effort; COVID Moonshot.

Why It Matters

Medicinal Chemistry powered by Machine Learning

Recent Developments

  1. 2020 Company founded

    PostEra was founded in 2020 per the company profile source on file.

    Source

Connected Reports

Connected Insights

Industries

PostEra is building a modern 21st century biopharma. We’re using our advances in machine learning to accelerate Medicinal Chemistry and bring more cures to patients. PostEra advances small molecule programs through partnerships with biopharma while also advancing its own internal pipeline. We’ve raised $26M from top investors and closed $1Bn in AI partnerships, signing multi-year agreements with Amgen, Pfizer and the NIH. PostEra also launched and led the world’s largest open-science drug discovery effort; COVID Moonshot.

Company information is based on publicly available sources and is reviewed periodically. If you represent this company and would like to request a correction, contact Brel.

Explore Related Intelligence

The AI Brief

Weekly company intelligence in your inbox.

Subscribe